A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.

doi:10.1016/j.clml.2015.02.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.

Clinical lymphoma, myeloma & leukemia - 1 Jul 2015

Cooper Brenda W, Kindwall-Keller Tamila L, Craig Michael D, Creger Richard J, Hamadani Mehdi, Tse William W, Lazarus Hillard M

Abstract excerpt

BACKGROUND: Midostaurin is a novel, orally available Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor that induces cell cycle arrest and apoptosis of leukemic cells expressing mutant and wild type FLT3 receptors, and has shown potential synergism with cytotoxic chemotherapy. PATIENTS AND METHODS: We conducted a phase I study of azacitidine (intravenous 75 mg/m(2) daily for 7 days) with escalating doses...

Topics

Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Azacitidine
Female
Humans
Leukemia, Myeloid, Acute
Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Middle Aged

Mutation

Neoplasm Recurrence, Local

Staurosporine

Treatment Outcome

fms-Like Tyrosine Kinase 3

Source

Open in PubMed Open full text

Identifiers

PMID: 25776192
DOI: 10.1016/j.clml.2015.02.017
PMCID: PMC4484305

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-25776192-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.PMID 25776192Read ↗

Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Semantic proximity Read ↗

Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis.Semantic proximity Read ↗

Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Semantic proximity Read ↗

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.Semantic proximity Read ↗

Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.Semantic proximity Read ↗

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.Semantic proximity Read ↗

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.Semantic proximity Read ↗

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.